UNION has built a differentiated mid-to late-stage clinical pipeline with drug candidates in large therapeutic areas.

*) Innovent Biologics has exclusive rights to oral orismilast and an option on topical orismilast for China, HK, Taiwan and Macau; UNION retains remaining worldwide rights.

**) IIT: Investigator initiated trial

Expanded access policy to be found here